Clinical Trial Update: An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis [Phase 2]

View source ↗

Summary

Phase 2 open-label trial evaluating standard-dose vs high-dose encorafenib + binimetinib in BRAFV600-mutant melanoma with brain metastases; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• Encorafenib (encorafenib)

Snippet

Sponsor: Pfizer | Conditions: Brain Metastases | Phase 2 | Status: TERMINATED | Results posted: 2023-05-31